Status: Recruiting
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
Participants needed: 150
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Jiangsu HengRui Medicine Co., Ltd.Updated: May 11, 2026Locations: 1
Eligibility criteria
Female aged 18 to 75 years (inclusive). [+9]
Presence of leptomeningeal metastasis/carcinomatous meningitis, spinal cord comp... [+12]